*Last Chance* Deadline To Submit Comments To Icer Is Tomorrow, May 8
The Institute for Clinical and Economic Review (ICER) is assessing the new class of CGRP inhibitor medicines for migraine prevention. Insurance companies will use ICER’s selesai report (as well as other information) when determining if they will cover these medicines, what tier the medicines will be in on the plans’ formularies, and what types of prior authorization or step therapy will be required.
ICER does not have a migraine patient or a headache specialist on the voting panel that will be making their selesai decision, so they truly do not have a personal or specialist understanding of migraine disease. This is why it is vital that ICER hear from migraine patients!
CHAMP, HMPF and Golden Graine have worked together to create an Updated Patient Guide that provides all the information you need to know on what to cover and how to submit your migraine story. The deadline for submissions is Tuesday, May 8, 2018.
It is critically important that ICER understands the migraine patient experience and that we speak with one loud and unified voice!
